Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IBA back on track to offload molecular imaging biz and focus on proton therapy

This article was originally published in Clinica

Executive Summary

Belgian proton therapy firm Ion Beam Applications (IBA) has finalised plans to sell a majority stake in its molecular imaging business, after agreeing to divest the Canadian portion of the unit separately. The move is part of a strategic decision to consolidate the company's business and focus on proton therapy, a spokesperson for IBA told Clinica. "IBA therefore decided to seek a partner to carry out the €100m investment needed to further develop the molecular business' existing platform and future molecules."

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel